Key Developments: Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,200JPY
26 Dec 2014
Price Change (% chg)

¥1 (+0.08%)
Prev Close
¥1,199
Open
¥1,199
Day's High
¥1,209
Day's Low
¥1,199
Volume
552,100
Avg. Vol
1,405,797
52-wk High
¥1,947
52-wk Low
¥1,095

Search Stocks

Latest Key Developments (Source: Significant Developments)

Dainippon Sumitomo Pharma Co Ltd to sell property and expects extraordinary profit for Q3 of FY 2015
Thursday, 30 Oct 2014 02:40am EDT 

Dainippon Sumitomo Pharma Co Ltd:To sell property including land and building located in Osaka, to HANSHIN ELECTRIC RAILWAY CO.,LTD., planned in early December, at price of 9,450 mln yen.Expects extraordinary profit of 7,680 mln yen for Q3 of FY ending March 2015 due to this selling.  Full Article

Dainippon Sumitomo Pharma Co Ltd announces joint development and license agreement for North America with respect to SB623 with SanBio Co., Ltd.
Friday, 26 Sep 2014 02:30am EDT 

Dainippon Sumitomo Pharma Co Ltd:The company and SanBio announce the two companies have entered into a joint development and license agreement for exclusive marketing rights in the U.S and Canada for SB623, a cell therapy for the treatment of patients with chronic stroke discovered and currently under development by SanBio.  Full Article

Dainippon Sumitomo Pharma Co Ltd to sell properties
Friday, 29 Aug 2014 02:00am EDT 

Dainippon Sumitomo Pharma Co Ltd:To sell an Osaka-based property for 6,345 mln yen to Sumitomo Realty & Development Co., Ltd in late September.To sell a Hyogo-based property for 3,421 mln yen to DAIWA HOUSE INDUSTRY CO.,LTD in late September.To sell an Osaka-based property for 770 mln yen to Hankyu Realty Co.,Ltd in late September.  Full Article

Dainippon Sumitomo Pharma Co Ltd expects extraordinary profit for Q2 of FY 2015
Friday, 29 Aug 2014 02:00am EDT 

Dainippon Sumitomo Pharma Co Ltd:Expects extraordinary profit of 8,241 mln yen for Q2 of FY ending March 2015.  Full Article

Dainippon Sumitomo Pharma raises mid-year consolidated net profit outlook for FY 2015
Wednesday, 30 Jul 2014 02:00am EDT 

Dainippon Sumitomo Pharma Co Ltd:Mid-year consolidated outlook for revenue of 178,000 mln yen, for fiscal year ending March 2015.Mid-year operating profit outlook of 12,000 mln yen.Mid-year ordinary profit outlook of 11,500 mln yen.Mid-year net profit outlook of 11,000 mln yen raised from 6,300 mln yen.Mid-year earnings per share outlook of 27.69 yen raised from 15.86 yen.Net profit outlook raised due to extraordinary profit caused by reorganization of idle assets.  Full Article

Dainippon Sumitomo Pharma announces results of clinical trails for anti-cancer drugs BBI608 and BBI503
Thursday, 5 Jun 2014 11:00pm EDT 

Dainippon Sumitomo Pharma Co Ltd:Announced results of clinical trails for BBI608 and BBI503 at the 2014 ASCO Annual Meeting.In phase I extension study of BBI608, neither significant difference in plasma exposure between the original formulation (DP1) and DP2A nor significant food effect was observed.The recommended dosing regimen for BBI608 in pivotal trials was determined to be about 500 mg bid q12 h and progression free survival and overall survival at 17 weeks and 39 weeks respectively.In phase Ib study of the cancer stem cell inhibitor BBI608, MTD was not determined and no new adverse events were observed, and the safety profile was similar to that of each agent as monotherapy and no significant pharmacokinetic interactions were observed.A phase I dose escalation study of BBI503 indicated that escalating doses from 10 mg to 450 mg once daily were administered to 26 patients and MTD was not reached.  Full Article

Dainippon Sumitomo Pharma to change English company name
Wednesday, 21 May 2014 05:45am EDT 

Dainippon Sumitomo Pharma Co Ltd:To change English company name to Sumitomo Dainippon Pharma Co., Ltd., effective June 19.  Full Article

Dainippon Sumitomo Pharma raises consolidated full-year outlook for FY 2014
Friday, 4 Apr 2014 02:00am EDT 

Dainippon Sumitomo Pharma Co Ltd:Says the company increased the consolidated full-year outlook for revenue to 387,000 million yen from 385,000 million yen for the fiscal year ended March 2014.Sees an increased operating profit forecast to 42,000 million yen from 35,000 million yen.Sees an increased ordinary profit forecast to 41,000 million yen from 34,000 million yen.Sees an increased net profit forecast to 20,000 million yen from 17,000 million yen.Sees an increased earnings per share to 50.34 yen from 42.79 yen.FY 2014 revenues of 381.29 billion yen, reported net profit of 18.80 billion yen – Thomson Reuters I/B/E/S.Comments the steady growth of business in North America, as well as cost down are the main reasons for the forecast.  Full Article

Dainippon Sumitomo Pharma and Takeda Pharmaceutical receive European Marketing Authorization for Latuda
Sunday, 30 Mar 2014 07:00pm EDT 

Dainippon Sumitomo Pharma Co Ltd and Takeda Pharmaceutical Co Ltd:Say European Commission has granted Marketing Authorization for once-daily oral Latuda for the treatment of schizophrenia in adults.The Marketing Authorization was based on a comprehensive clinical trial program of eight studies, which included placebo and active comparators.  Full Article

R&I affirms Dainippon Sumitomo Pharma’s rating at "A" and rating outlook stable
Tuesday, 25 Mar 2014 02:00am EDT 

Dainippon Sumitomo Pharma Co Ltd:Rating and Investment Information, Inc. (R&I) has affirmed the rating on the company at "A".The rating outlook is stable.  Full Article

Search Stocks